AN2 Therapeutics (ANTX) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results